About

HIV-1 is the most common form of HIV, the virus that attacks the immune system's infection-fighting cells and, without treatment, leaves the body unable to defend itself against illness. Bixlenvo combines two medicines in one tablet: bictegravir blocks an enzyme the virus needs to insert its genetic material into human cells, while lenacapavir binds the virus's protective shell and disrupts it. Together they attack HIV at two different points, which may help keep the virus suppressed in people already on treatment.